Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Duchenne Muscular Dystrophy Market is Anticipated to Grow With a CAGR of 31.8% for the Study Period of 2017-2030: DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

07 May, 2020, 12:00 GMT

Share this article

Share toX

Share this article

Share toX

LAS VEGAS, May 7, 2020 /PRNewswire/ -- The growth of Duchenne Muscular Dystrophy (DMD) Market is anticipated to increase because of an increasing incidence of DMD patients as well as the launch of emerging drugs in the 7MM.

DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecast-2030" to its portfolio.

Key Highlights from the report are:

  • As per the DelveInsight analysis, the total diagnosed Duchenne Muscular Dystrophy prevalent population in the 7 MM was 27,685 in 2017. 
  • The total diagnosed prevalent cases of DMD patients were found to be maximum in the age-group of 8–13 year and 14–19 year in the United States in 2017. 
  • The treatment for DMD patients is the standard care along with the new upcoming therapeutic strategies covering Genetic Therapies, Cell therapy using muscle precursor cells or stem cells, Membrane stabilization and upregulation of cytoskeletal proteins and secondary cascades treatment. 
  • Duchenne Muscular Dystrophy market size in the 7MM is expected to increase during the study period. As per the estimates, the highest contribution in the market size of DMD is from the United States, followed by EU-5 countries and Japan. 

Request for free sample pages to know more on Duchenne Muscular Dystrophy Market Forecast   

Duchenne Muscular Dystrophy is a progressive form of muscular dystrophy, which usually occurs in males, though in rare cases may affect females as well, causing progressive weakness and loss (atrophy) of skeletal and heart muscles.   

The disease epidemiology covered in the report proffers historical as well as forecasted Duchenne Muscular Dystrophy epidemiology, which is segmented as Diagnosed Prevalent Population of DMD, Age-specific Diagnosed Prevalence of DMD, Mutation-specific Diagnosed Prevalence of DMD and Diagnosed Prevalence of Associated Comorbidities in DMD in the 7MM market from 2017 to 2030. 

The report also covers Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy, including several mutations such as Large Mutations, Small Mutations and Point Mutations with major proportion for deletions in Large Mutations subgroup.

Click here to know more on Duchenne Muscular Dystrophy pipeline

Duchenne Muscular Dystrophy report encloses the detailed analysis of DMD marketed drugs and mid and late-stage pipeline drugs.

The therapies that are approved for the DMD treatment are Vyondys 53 (Golodirsen), Emflaza, Exondys 51, Translarna along with many more.

Drugs covered in the report are:-

There are several key players robustly involved in developing potential products such as

  • Casimersen
  • SRP-9001
  • Puldysa (Idebenone)
  • Givinostat
  • Edasalonexent
  • Viltolarsen
  • PF-06939926
  • Vamorolone
  • TAS-205
  • Pamrevlumab (FG-3019)
  • Allogeneic Cardiosphere-Derived Cells (CAP-1002)
  • DS-5141b

And many others

Key Players covered in the DMD market report are:-

  • Sarepta Therapeutics
  • Italfarmaco
  • Catabasis Pharmaceuticals
  • Nippon Shinyaku (NS Pharma)
  • Pfizer
  • Santhera Pharmaceuticals/ReveraGen BioPharma
  • Taiho Pharmaceutical
  • FibroGen
  • Capricor
  • Daiichi Sankyo

And many others

The reasons for buying this report:

  • The report proffers an overview of pathophysiology, various diagnostic approaches and Duchenne Muscular Dystrophy treatment algorithm, including detailed chapters for marketed products and emerging therapies.
  • Historical and forecasted DMD epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.
  • Detailed historical and forecasted Duchenne Muscular Dystrophy market covering the United States, EU5 and Japan from 2017-2030. 
  • Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities. 
  • Detailed DMD market size by therapies, covering the United States, EU5 and Japan from 2017-2030. 
  • Reimbursement scenario and Key Opinion Leader Views.

Table of Contents

1

Key Insights

2

Duchenne Muscular Dystrophy Market Overview at a Glance

3

DMD Disease Background and Overview

4

Recognized Establishments

5

Duchenne Muscular Dystrophy Epidemiology and Patient Population

6

Country Wise-Epidemiology of DMD

6.1

United States

6.2

EU5 Countries

6.3

Germany

6.4

France

6.5

Italy

6.6

Spain

6.7

United Kingdom

6.8

Japan

7

Duchenne Muscular Dystrophy Treatment

8

General Guidelines on DMD

9

United States Guidelines on Duchenne Muscular Dystrophy

10

European Guidelines on Duchenne Muscular Dystrophy

11

Unmet Needs

12

DMD Marketed Drugs

13

Duchenne Muscular Dystrophy Emerging Drugs

13.1

Key Cross Competition

13.2

Casimersen: Sarepta Therapeutics

13.3

Puldysa (Idebenone): Santhera Pharmaceuticals

13.4

Givinostat: Italfarmaco

13.5

Edasalonexent: Catabasis Pharmaceuticals

13.6

Viltolarsen: Nippon Shinyaku (NS Pharma)

13.7

PF-06939926: Pfizer

13.8

Vamorolone: Santhera Pharmaceuticals/ReveraGen BioPharma

13.9

TAS-205: Taiho Pharmaceutical

13.10

Pamrevlumab (FG-3019): FibroGen

13.11

SRP-9001: Sarepta Therapeutics

13.12

Allogeneic Cardiosphere-Derived Cells (CAP-1002): Capricor

13.13

DS-5141b: Daiichi Sankyo

14

Duchenne Muscular Dystrophy 7 Major Market Analysis

15

The United States Market Outlook

16

EU-5 Countries: Market Outlook

16.1

Germany

16.2

France

16.3

Italy

16.4

Spain

16.5

United Kingdom

17

Japan: Market Outlook

18

Case Reports

19

Market Drivers

20

Market Barriers

21

SWOT Analysis for Duchenne Muscular Dystrophy

22

Appendix

23

DelveInsight Capabilities

24

Disclaimer

25

About DelveInsight

Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Related Reports:-

  • Duchenne Muscular Dystrophy Epidemiology Forecast to 2030
    DelveInsight's Duchenne Muscular Dystrophy - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Duchenne Muscular Dystrophy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Duchenne Muscular Dystrophy Pipeline Insights, 2020
    Duchenne Muscular Dystrophy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Duchenne Muscular Dystrophy market.

Contact us:
Shruti Thakur
info@delveinsight.com
+91-9650213330
DelveInsight

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

DelveInsight's Cancer Cachexia Market Insights report includes a comprehensive understanding of current treatment practices, cancer cachexia emerging ...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

DelveInsight's Bispecifics/BiTE Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Equipment

Medical Equipment

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.